Dr. Richard Scolyer: A Legacy in Melanoma Research

Dr. Richard Scolyer, a distinguished Australian pathologist who significantly advanced the understanding and diagnosis of melanoma in Australia, passed away on June 7 in Sydney at the age of 59. His death was announced by Prime Minister Anthony Albanese, who mentioned that Dr. Scolyer would be honored with a state funeral.

In early 2023, Dr. Scolyer received a diagnosis of advanced glioblastoma but managed to surpass the typical survival rate for this aggressive cancer. Over the subsequent years, he shared his journey through experimental immunotherapy on social media and in interviews, culminating in his 2024 autobiography titled “Brainstorm,” co-authored with journalist Garry Maddox.

Prime Minister Albanese remarked on Dr. Scolyer’s bravery saying, “The cancer specialist who became his own subject… will always be remembered.”

Many Australians, including Mr. Albanese, were familiar with Dr. Scolyer’s groundbreaking work on melanoma and the details of his treatment. In 2025, the government announced a contribution of $5.9 million to establish the Richard Scolyer Chair in Brain Research at the Chris O’Brien Lifehouse, a cancer treatment center in Sydney.

For over two decades, Dr. Scolyer focused on melanoma—the most fatal skin cancer—at Royal Prince Alfred Hospital and the Melanoma Institute Australia. Melanoma is a prominent concern in Australia, heavily linked to the sun exposure received by its largely fair-skinned population.

At the Melanoma Institute, where he served as a medical director for seven years, Dr. Scolyer contributed to developing the Biospecimen Bank, aiding research with samples from various bodily fluids. He also played a key role in the Australian Melanoma Genome Project, focused on mapping genetic mutations associated with the disease. His expertise was highly regarded both nationally and internationally.

“His vast knowledge and unmatched skill in tissue diagnosis were invaluable,” Dr. Georgina Long, the institute’s medical director, noted in a statement.

Dr. Scolyer’s work shed light on the mechanisms behind melanoma’s spread to the brain and identified features that can predict patient outcomes more accurately. His insights into pathology have had lasting implications for treatment responses.

In 2024, he and Dr. Long were honored as joint Australians of the Year for their instrumental efforts in improving the five-year survival rate for advanced melanoma from below five percent to over fifty percent. “It’s as Aussie as our golden beaches,” Dr. Scolyer reflected during his acceptance speech.

Richard Anthony Scolyer was born on December 16, 1966, in Launceston, Tasmania. His mother, Jenny, a teacher, suffered strokes early in his life, and his father, Maurice, underwent a skin graft for what was initially thought to be melanoma.

After achieving a bachelor’s degree in medical science from the University of Tasmania in 1987 and further degrees in medicine and surgery, Dr. Scolyer explored various medical fields before specializing in pathology. He became a senior staff specialist in anatomical pathology at Royal Prince Alfred Hospital, beginning his tenure at the melanoma institute in 2001.

Having published over 800 peer-reviewed articles, Dr. Scolyer was a highly regarded collaborator in melanoma research. During his career, he was involved in crucial global clinical trials related to immunotherapy.

Dr. Scolyer is survived by his wife, Dr. Katie Nicoll; their three children, Emily, Lucy, and Matthew; and his brother, Mark. He faced a personal health battle himself when a seizure in 2023 led to his glioblastoma diagnosis, a situation he described as deeply distressing.

In his autobiography, he mentioned his struggle, expressing that he knew his diagnosis was devastating. In Sydney, Dr. Long developed a treatment plan that included immunotherapy drugs, surgery, radiation, and a personalized cancer vaccine, informed by her successes with other patients.

After his treatment, he responded well, but by 2025, the cancer had returned. “It’s heartbreaking,” he articulated to a reporter. “I’m not ready to die.” Some of the drugs administered to him are currently being evaluated in clinical trials aimed at improving glioblastoma treatment.

Dr. Mustafa Khasraw, leading one of the trials, emphasized the need for innovative ideas in addressing such challenging diagnoses. “While it is difficult to find meaning in such a devastating diagnosis,” he stated, “Richard’s experience helped raise awareness of the challenges faced by glioblastoma patients and the ongoing need to push scientific boundaries.”